ClinicaliQ Trial Snapshot
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Active Not Recruiting • Phase II • Neurology • NCT05819359.
- New drug BIA 28-6156 tested against placebo to slow motor decline in GBA gene-linked Parkinson's disease over 78 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Conditions: Parkinson's Disease Interventions: BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo Lead Sponsor: Bial R&D Investments, S.A. Planned Enrollment: 237 participants